OBJECTIVE: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. STUDY DESIGN: A double-blind, placebo-controlled randomized trial of escitalopram 10-20mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. MAIN OUTCOME MEASURES: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). RESULTS: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p<0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p=0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p=0.045). CONCLUSIONS: Treatment with escitalopram 10-20mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.
OBJECTIVE: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. STUDY DESIGN: A double-blind, placebo-controlled randomized trial of escitalopram 10-20mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. MAIN OUTCOME MEASURES: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). RESULTS: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p<0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p=0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p=0.045). CONCLUSIONS: Treatment with escitalopram 10-20mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.
Authors: Kristen B Van Dole; Robert F DeVellis; Rebekkah D Brown; Michele L Jonsson Funk; Bradley N Gaynes; Rachel E Williams Journal: Menopause Date: 2012-02 Impact factor: 2.953
Authors: Claudio N Soares; Helga Arsenio; Hadine Joffe; Bettina Bankier; Paolo Cassano; Laura F Petrillo; Lee S Cohen Journal: Menopause Date: 2006 Sep-Oct Impact factor: 2.953
Authors: J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn Journal: Maturitas Date: 1996-07 Impact factor: 4.342
Authors: Janet S Carpenter; Katherine A Guthrie; Joseph C Larson; Ellen W Freeman; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Andrea Z LaCroix Journal: Fertil Steril Date: 2012-04-03 Impact factor: 7.490
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: Janet S Carpenter; Giorgos Bakoyannis; Julie L Otte; Chen X Chen; Kevin L Rand; Nancy Woods; Katherine Newton; Hadine Joffe; JoAnn E Manson; Ellen W Freeman; Katherine A Guthrie Journal: Menopause Date: 2017-08 Impact factor: 3.310
Authors: Bette Caan; Andrea Z LaCroix; Hadine Joffe; Katherine A Guthrie; Joseph C Larson; Janet S Carpenter; Lee S Cohen; Ellen W Freeman; JoAnn E Manson; Katherine Newton; Susan Reed; Kathy Rexrode; Jan Shifren; Barbara Sternfeld; Kris Ensrud Journal: Menopause Date: 2015-06 Impact factor: 3.310
Authors: Susan J Diem; Andrea Z LaCroix; Susan D Reed; Joseph C Larson; Katherine M Newton; Kristine E Ensrud; Nancy F Woods; Katherine A Guthrie Journal: Menopause Date: 2020-10 Impact factor: 3.310
Authors: Nancy Fugate Woods; Chancellor Hohensee; Janet S Carpenter; Lee Cohen; Kristine Ensrud; Ellen W Freeman; Katherine A Guthrie; Hadine Joffe; Andrea Z LaCroix; Julie L Otte Journal: Menopause Date: 2016-02 Impact factor: 3.310
Authors: Susan D Reed; Katherine A Guthrie; Katherine M Newton; Garnet L Anderson; Cathryn Booth-LaForce; Bette Caan; Janet S Carpenter; Lee S Cohen; Andrea L Dunn; Kristine E Ensrud; Ellen W Freeman; Julie R Hunt; Hadine Joffe; Joseph C Larson; Lee A Learman; Robin Rothenberg; Rebecca A Seguin; Karen J Sherman; Barbara S Sternfeld; Andrea Z LaCroix Journal: Am J Obstet Gynecol Date: 2013-11-08 Impact factor: 10.693